VERTEX PHARMACEUTICALS INC / MA Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
VERTEX PHARMACEUTICALS INC / MA (VRTX) had Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $1.70 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value
us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-04
- 2026-06-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $1.70B.
- 2025-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $1.51B.
- 2023-12-31: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $6.39B.
- 2023-09-30: Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $4.86B.
| Period end | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One | Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One as first filed |
|---|---|---|
| 2026-06-30 | $1.70B 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $1.51B 10-Q · filed 2026-08-04 | |
| 2023-12-31 | $6.39B 10-K · filed 2024-02-15 | |
| 2023-09-30 | $4.86B 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $4.94B 10-Q · filed 2023-08-02 | |
| 2023-03-31 | $6.56B 10-Q · filed 2023-05-02 | |
| 2022-12-31 | $5.53B 10-K · filed 2024-02-15 | |
| 2022-09-30 | $4.09B 10-Q · filed 2022-10-28 | |
| 2022-06-30 | $5.68B 10-Q · filed 2022-08-05 | |
| 2022-03-31 | $4.82B 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $3.91B 10-K · filed 2023-02-10 | |
| 2021-09-30 | $4.01B 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $4.13B 10-Q · filed 2021-07-30 | |
| 2021-03-31 | $4.36B 10-Q · filed 2021-04-30 | |
| 2020-12-31 | $3.53B 10-K · filed 2022-02-09 | $3.53B 10-K · filed 2021-02-11 |
| 2020-09-30 | $3.51B 10-Q · filed 2020-10-30 | |
| 2020-06-30 | $2.94B 10-Q · filed 2020-07-31 | |
| 2020-03-31 | $2.16B 10-Q · filed 2020-05-01 | |
| 2019-12-31 | $1.14B 10-K · filed 2021-02-11 | |
| 2019-09-30 | $1.78B 10-Q · filed 2019-10-31 | |
| 2018-12-31 | $1.65B 10-K · filed 2020-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |